Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NANT Pancreatic Cancer Vaccine
- Development stage
- Unknown
- Lead developer
- ImmunityBio
- Modality
- Vaccines & Immunotherapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes, Cell Therapies, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous, Oral, Subcutaneous
01
Overview
The NANT Pancreatic Cancer Vaccine is a multi-modal, combination immunotherapy regimen in development for the treatment of pancreatic cancer, especially for patients who have progressed on or after standard-of-care therapies. The approach integrates low-dose (metronomic) chemoradiation to induce damage-associated molecular pattern (DAMP) signals and expose tumor antigens, delivery of tumor antigen vaccines (adenoviral, yeast-based, and fusion-protein vaccines targeting KRAS and other tumor antigens), stimulation of natural killer (NK) and T-cells using the IL-15 superagonist N-803 (Anktiva), and administration of engineered, PD-L1-targeted, high-affinity off-the-shelf NK cell therapy (PDL1-t-haNK cells). The therapy aims to coordinate engagement of both the innate and adaptive immune systems to induce durable anti-tumor responses. The regimen is being tested in clinical trials (notably the QUILT 88 and QUILT 3.070 studies) in metastatic pancreatic cancer and is developed by ImmunityBio, building on earlier work by NantKwest.
- Brand names
- NANT Pancreatic Cancer Vaccine
- Other names
- Nant Cancer VaccineNANT Pancreatic Cancer Vaccine RegimenNCV
02
Targets
γc family (Common γ-chain receptor family (IL-2/4/7/9/15/21))DNACD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on NANT Pancreatic Cancer Vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NANT Pancreatic Cancer Vaccine.